Williams & Novak’s Ensysce Biosciences ENSC Stock Holding History

Williams & Novak’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,850	Closed	-$16.4K	–	150
2025 Q4	$16.4K	Buy	+17,850	New	+$33.1K	0.01%	141

Other funds holding ENSC

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Williams & Novak's ENSC Position: Q1 2026 in Review

Williams & Novak sold out of Ensysce Biosciences (ENSC) in Q1 2026, closing a stake of 17,850 shares — an estimated $16.4K sold.

Williams & Novak first reported a position in ENSC in Q4 2025 and held it in 1 quarter. The position peaked at $16.4K in Q4 2025. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

Williams & Novak reported no remaining Ensysce Biosciences position as of Q1 2026 after selling out during the quarter.
Williams & Novak sold 17,850 Ensysce Biosciences shares in Q1 2026, an estimated $16.4K.
Williams & Novak first reported a position in Ensysce Biosciences in Q4 2025 and held it in 1 quarter.
Williams & Novak's Ensysce Biosciences position peaked at $16.4K in Q4 2025.
15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Williams & Novak's 13F filing for Q1 2026, filed 21 Apr 2026.